Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold
by Amy Steele · The Cerbat GemWall Street Zen cut shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) from a buy rating to a hold rating in a report released on Saturday.
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.
Get Our Latest Stock Analysis on SPRO
Spero Therapeutics Trading Down 4.0%
SPRO stock opened at $2.37 on Friday. The firm has a 50 day simple moving average of $2.36 and a 200-day simple moving average of $2.30. The company has a market capitalization of $133.53 million, a P/E ratio of -3.00 and a beta of 1.45. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.22.
Insider Buying and Selling at Spero Therapeutics
In other news, insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.36, for a total value of $207,484.12. Following the completion of the sale, the insider directly owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. The trade was a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.50% of the company’s stock.
Hedge Funds Weigh In On Spero Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the business. GSK plc acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth $21,414,000. Stonepine Capital Management LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $455,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Spero Therapeutics during the 3rd quarter valued at about $283,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Spero Therapeutics during the 4th quarter valued at about $306,000. Finally, Squarepoint Ops LLC acquired a new stake in Spero Therapeutics during the fourth quarter worth about $278,000. Institutional investors and hedge funds own 25.60% of the company’s stock.
About Spero Therapeutics
Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.
The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.